title: Fragonomics: fragment-based drug discovery.
abstract: The use of smaller molecules (fragments) in the drug discovery process has led to success in delivering novel leads for many different targets. This process is a highly integrated process, starting from library design to screening and medicinal chemistry. An overview of this process is presented with particular emphasis placed on the NMR aspect of screening.
authors.affiliation: Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, IN 46285, USA. zartler_edward@lilly.com
authors.forename: Edward R
authors.initials: ER
authors.lastname: Zartler
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Shapiro
mesh_terms: D018360:Crystallography, X-Ray; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D004364:Pharmaceutical Preparations / Q000737:chemistry*
chemical_list: D004364:Pharmaceutical Preparations